Dyne Therapeutics

Overview

Clinical-stage biotech founded 2019 developing targeted nucleic acid medicines using the FORCE platform (Fab-TFR1 conjugate) for neuromuscular diseases; pursuing first BLA approval for DMD exon 51 in early 2027. Dyne Therapeutics was founded in 2019 and expects approval of its first drug (Dyne-251 for DMD exon 51) in early 2027, representing roughly seven to eight years from founding to potential approval. Dyne Therapeutics' pipeline includes Dyne-101 for DM1 (in registrational phase 3 trial with accelerated approval pathway), Dyne-251 for DMD exon 51 (BLA filed), FSHD program near IND, and additional DMD exons plus an enzyme conjugate for Pompe disease. (Segment 1 (00:00-05:00))